POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. We concentrate mainly on the development phase of a drug's life. We believe that there are and will continue to be more and more opportunities in need of rapid development. Our initial focus is developing products for migraine therapy, a multi-billion dollar global market. POZEN has three product candidates, each designed with a unique profile to treat different stages of migraine attacks - mild, moderate and severe. Combined, these product candidates may offer patients and physicians the ability to customize migraine therapy. We plan to work with partners to commercialize our product candidates, which we project to have a combined market potential of more than $1 billion.